AbbVie Inc. stands to expand its position in the crowded migraine space with Phase III data showing its approved oral anti-CGRP agent Qulipta (atogepant) is effective as a preventive treatment of chronic migraine in adults. The new data could add another commercial peg to AbbVie's already large presence in migraine while also giving it a potential edge over competitors.
The company said 10 March that the Phase III PROGRESS trial testing Qulipta once daily at 60mg or twice daily...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)